Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma

NCT03168061 is registered in ClinicalTrials.gov with NanoCarrier Co., Ltd. as lead sponsor.

NCT NCT03168061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03168061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma
Lead sponsor
NanoCarrier Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2017
Completion date
July 31, 2020
Enrollment
150 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic sarcoma, sarcoma, soft tissue sarcoma, solid tumor